Transgene S.A.

TNGFR0005175080

Filings

82 filings

All Inside information82 Share buyback6 Annual financial report6 Quarterly financial information4 AGM documents4 Half-year financial report4 Universal registration document2

25/06/2026
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026
Inside informationFR
22/06/2026
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
Inside informationFR
26/05/2026
Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
Inside informationFR
22/05/2026
Transgene’s Combined General Meeting of May 22, 2026
Inside informationFR
13/04/2026
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
Inside informationFR
07/04/2026
Transgene to Participate in Upcoming Investor Meetings
Inside informationFR
02/04/2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Inside informationFR
26/03/2026
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress
Inside informationFR
24/03/2026
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
Inside informationFR
04/02/2026
Transgene Announces Financial Calendar for 2026
Inside informationFR
23/01/2026
Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero
Inside informationFR
09/01/2026
Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
Inside informationFR
17/12/2025
Transgene to Participate in Upcoming Investor Meetings
Inside informationFR
27/11/2025
Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets
Inside informationFR
26/11/2025
Transgene Successfully Completes a Fundraising of c. €105 Million
Inside informationFR
25/11/2025
DOCUMENT D'INFORMATION ETABLI CONFORMEMENT À L'ANNEXE IX DU REGLEMENT (UE) 2017/1129 DU PARLEMENT EUROPEEN ET DU CONSEIL DU 14 JUIN 2017, TEL QUE MODIFIE
Inside informationFrench
25/11/2025
Correction: Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
Inside informationFR
25/11/2025
Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
Inside informationFR
25/11/2025
Correction: Transgene launches a fundraising campaign for approximately 105 million euros
Inside informationFR
25/11/2025
Transgene launches a fundraising campaign for approximately 105 million euros
Inside informationFR
06/11/2025
Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
Inside informationFR
04/11/2025
Transgene fait le point sur ses activités et sa situation financière au troisième trimestre 2025
Inside informationFrench
04/11/2025
Transgene Provides Business and Financial Update for Q3 2025
Inside information
04/11/2025
Les nouvelles données d’immunologie de la Phase I de TG4050 présentées au SITC 2025 démontrent son potentiel prometteur à réduire le risque de récidive
Inside informationFrench
04/11/2025
New Phase I Immunological Data Presented at SITC 2025 Support TG4050’s Potential Role in Preventing Cancer Relapse
Inside information
20/10/2025
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
Inside informationFR
13/10/2025
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
Inside informationFR
03/10/2025
Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025
Inside informationFR
16/09/2025
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data ? Randomization to be Completed in Phase II Part in Q4 2025
Inside informationFR
28/07/2025
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001, at ESMO 2025
Inside informationFR
09/07/2025
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director
Inside information
19/06/2025
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
Inside informationFR
13/06/2025
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
Inside informationFR
03/06/2025
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025
Inside informationFR
01/06/2025
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
Inside informationFR
22/05/2025
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
Inside informationFR
15/05/2025
Transgene's Combined General Meeting of May 15, 2025
Inside informationFR
23/04/2025
Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025
Inside informationFR
01/04/2025
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations
Inside informationFR
27/03/2025
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ? Strong Outlook for 2025
Inside informationFR
11/03/2025
Transgene to Participate in Upcoming Investor Meetings
Inside informationFR
06/02/2025
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
Inside informationFR
21/01/2025
Transgene to Participate in the Biomed Forum Investor Conference
Inside informationFR

About

ISIN: FR0005175080
Ticker: TNG
LEI: 969500PDJW8N0FSGGK69
Country of registration: FR
Last filing: 25/06/2026, 07:30

Sparse profile

The AMF publishes neither sector nor description. These fields are enriched from Wikidata where a match exists.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive